目标导向液体治疗在自体乳房重建中减少输液量且不增加并发症
单中心回顾性研究比较2010-2017年777例自体乳房重建患者,其中2015年4月后实施ERAS联合目标导向液体治疗(GDFT)的312例与之前的465例对比。GDFT组总输液量更少、尿量更低、更常用血管升压药、住院时间更短,而并发症无差异。结论认为GDFT联合审慎使用血管升压药安全,不增加发病率。
要点
- GDFT组总输液量中位数3750 mL,显著低于非GDFT组的5000 mL(p<0.001)。
- GDFT组血管升压药使用比例47%,高于非GDFT组的35%(p<0.001)。
- 两组并发症无差异,GDFT组住院时间更短(中位4天 vs 5天,p<0.001)。
核心结论
- GDFT作为ERAS的一部分,联合审慎使用血管升压药,在自体乳房重建患者中安全且不增加发病率。
研究设计与样本
- 单中心回顾性综述,纳入2010年1月至2017年4月自体乳房重建患者777例,其中ERAS-GDFT组312例,pre-ERAS组465例。
主要发现
- ERAS组总输液量中位数3750 mL(IQR 3000-4500 mL),pre-ERAS组5000 mL(IQR 4000-6400 mL),p<0.001。
- ERAS组尿量更低,血管升压药使用比例47% vs 35%(p<0.001),住院时间中位数4天(4-5) vs 5天(4-6),p<0.001。
- 两组主要并发症(如皮瓣失败)和次要并发症(如血清肿)无差异。
临床怎么用
- 在自体乳房重建中可实施ERAS框架下的GDFT,根据血流动力学指标给予液体和血管活性药物,以减少输液量并缩短住院时间。
局限性
- 单中心回顾性设计,GDFT组与pre-ERAS组存在时间偏倚,结果需前瞻性研究验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Aggressive or restricted perioperative fluid management has been shown to increase complications in patients undergoing microsurgery. Goal-directed fluid therapy (GDFT) aims to administer fluid, vasoactive agents, and inotropes according to each patient's hemodynamic indices. This study assesses GDFT impact on perioperative outcomes of autologous breast reconstruction (ABR) patients, as there remains a gap in management understanding. We hypothesize that GDFT will have lower fluid administration and equivocal outcomes compared to patients not on GDFT. METHODS: A single-center retrospective review was conducted on ABR patients from January 2010-April 2017. An enhanced recovery after surgery (ERAS) using GDFT was implemented in April 2015. With GDFT, patients were administered intraoperative fluids and vasoactive agents according to hemodynamic indices. Patients prior to April 2015 were included in the pre-ERAS cohort. Primary outcomes included the amount and rate of fluid delivery, urine output (UOP), vasopressor administration, major (i.e., flap failure) and minor (i.e., seroma) complications, and length of stay (LOS). RESULTS: Overall, 777 patients underwent ABR (ERAS: 312 and pre-ERAS: 465). ERAS patients received significantly less total fluid volume (ERAS median: 3750 mL [IQR: 3000-4500 mL]; pre-ERAS median: 5000 mL [IQR 4000-6400 mL]; and p<0.001), had lower UOP, were more likely to receive vasopressor agents (47% vs 35% and p<0.001), and had lower LOS (ERAS: 4 days [4-5]; pre-ERAS: 5 [4-6]; and p<0.001) as compared to pre-ERAS patients. Complications did not differ between cohorts. CONCLUSIONS: GDFT, as part of ERAS, and the prudent use of vasopressors were found to be safe and did not increase morbidity in ABR patients. GDFT provides individualized perioperative care to the ABR patient.
引用
- Polanco TO, Shamsunder MG, Hicks MEV, et al. Goal-directed fluid therapy in autologous breast reconstruction results in less fluid and more vasopressor administration without outcome compromise. J Plast Reconstr Aesthet Surg. 2021. PMID: 33745850. doi:10.1016/j.bjps.2021.01.017
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。